Upfront investment phase of the depression biomarker business
First written in FY2016-Q4. 14 of 32 entries say "Worsened", first in FY2017-Q1. Latest entry: FY2024.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2016.
0 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「As a result, revenue was ¥158.818 million, up 234.4% year on year, and the segment loss after allocation of company-wide expenses was ¥90.532 million, compared with a segment loss of ¥142.627 million in the previous consolidated fiscal year.」
The Healthcare Solutions business posted a significant increase in revenue, while the segment loss narrowed from ¥142.627 million to ¥90.532 million. - FY2024-Q3MitigatedAnnual report
「As a result, revenue was ¥152.192 million, up 415.6% year on year, and the segment loss after allocation of company-wide expenses was ¥47.446 million, compared with a segment loss of ¥110.321 million in the same period of the previous year.」
The Healthcare Solutions business posted a significant increase in revenue, while the segment loss narrowed from ¥110.321 million in the same period of the previous year to ¥47.446 million. - FY2024-Q2MitigatedAnnual report
「As a result, revenue was ¥115.910 million, up 410.2% year on year, and the segment loss after allocation of company-wide expenses was ¥23.025 million, compared with a segment loss of ¥69.357 million in the same period of the previous year.」
The Healthcare Solutions business posted a significant increase in revenue, while the segment loss narrowed from ¥69.357 million in the same period of the previous year to ¥23.025 million. - FY2024-Q1MitigatedAnnual report
「As a result, revenue was ¥13.983 million, up 105.4% year on year, and the segment loss after allocation of company-wide expenses was ¥34.629 million, compared with a segment loss of ¥37.251 million in the same period of the previous year.」
The Healthcare Solutions business posted higher revenue, while the segment loss narrowed from ¥37.251 million in the same period of the previous year to ¥34.629 million. - FY2023WorsenedAnnual report
「Meanwhile, the segment loss after allocation of company-wide expenses was ¥142.627 million, compared with a segment loss of ¥140.842 million in the previous consolidated fiscal year, as the company focused on R&D for new businesses and other initiatives, increasing R&D expenses.」
The Healthcare Solutions business posted higher revenue, while the segment loss widened from ¥140.842 million to ¥142.627 million due to increased R&D expenses. - FY2023-Q3WorsenedAnnual report
「As a result, revenue was ¥29.520 million, up 990.8% year on year, and the segment loss after allocation of company-wide expenses was ¥110.321 million, compared with a segment loss of ¥89.714 million in the same period of the previous year.」
The Healthcare Solutions business posted a significant increase in revenue, while the segment loss widened from ¥89.714 million in the same period of the previous year to ¥110.321 million. - FY2023-Q2WorsenedAnnual report
「As a result, revenue was ¥22.716 million, up 881.5% year on year, and the segment loss after allocation of company-wide expenses was ¥69.357 million, compared with a segment loss of ¥56.258 million in the same period of the previous year.」
The Healthcare Solutions business posted a significant increase in revenue, while the segment loss widened from the same period of the previous year. - FY2023-Q1WorsenedAnnual report
「As a result, revenue was ¥6.809 million, compared with revenue of ¥0.004 million in the same period of the previous year, and the segment loss after allocation of company-wide expenses was ¥37.251 million, compared with a segment loss of ¥24.914 million in the same period of the previous year.」
The Healthcare Solutions business posted higher revenue, while the segment loss widened from ¥24.914 million in the same period of the previous year to ¥37.251 million. - FY2022WorsenedAnnual report
「As a result of continuing contract research testing and other activities, revenue was ¥2.856 million, down 36.2% year on year. The segment loss was ¥140.842 million, compared with a segment loss of ¥101.980 million in the same period of the previous year, reflecting increased R&D investment.」
The Healthcare Solutions business posted lower revenue, while the segment loss widened from ¥101.980 million to ¥140.842 million due to increased R&D investment. - FY2022-Q3WorsenedAnnual report
「As a result, revenue was ¥2.706 million, up 9.5% year on year, and the segment loss was ¥89.714 million, compared with a segment loss of ¥80.036 million in the same period of the previous year.」
The Healthcare Solutions business posted higher revenue, while the segment loss widened from ¥80.036 million in the same period of the previous year to ¥89.714 million. - FY2022-Q2MitigatedAnnual report
「As a result, revenue was ¥2,314 thousand, up 8.5% year on year, and the segment loss after allocation of company-wide expenses was ¥56,258 thousand, compared with a segment loss of ¥56,630 thousand in the same period of the previous year.」
The Healthcare Solutions business posted higher revenue, while the segment loss narrowed slightly from ¥56.630 million in the same period of the previous year to ¥56.258 million. - FY2022-Q1MitigatedAnnual report
「As a result, revenue was ¥4 thousand, down 99.5% year on year, and the segment loss after allocation of company-wide expenses was ¥24,914 thousand, compared with a segment loss of ¥30,662 thousand in the same period of the previous year.」
The healthcare solutions business recorded a substantial decline in revenue, while the segment loss after allocation of company-wide expenses narrowed from ¥30,662 thousand in the same period of the previous year to ¥24,914 thousand. - FY2021MitigatedAnnual report
「The segment loss was ¥70,632 thousand, compared with a segment loss of ¥160,824 thousand in the same period of the previous year, as a result of efforts to spend research and development expenses efficiently.」
The biomarker business continued to record a loss, but the loss narrowed from ¥160,824 thousand in the same period of the previous year to ¥70,632 thousand. - FY2021-Q3MitigatedAnnual report
「As a result, revenue was ¥2,472 thousand, down 15.4% year on year, and the segment loss was ¥57,616 thousand, compared with a segment loss of ¥122,412 thousand in the same period of the previous year.」
The biomarker business recorded lower revenue, while the segment loss narrowed from ¥122,412 thousand in the same period of the previous year to ¥57,616 thousand. - FY2021-Q2MitigatedAnnual report
「As a result, revenue was ¥2,133 thousand, up 49.0% year on year, and the segment loss was ¥43,776 thousand, compared with a segment loss of ¥79,847 thousand in the same period of the previous year.」
The biomarker business recorded higher revenue, while the segment loss narrowed from ¥79,847 thousand in the same period of the previous year to ¥43,776 thousand. - FY2021-Q1MitigatedAnnual report
「As a result, revenue was ¥881 thousand, up 71.8% year on year, and the segment loss was ¥23,728 thousand, compared with a segment loss of ¥32,967 thousand in the same period of the previous year.」
The biomarker business recorded higher revenue, while the segment loss narrowed from ¥32,967 thousand in the same period of the previous year to ¥23,728 thousand. - FY2020MitigatedAnnual report
「As a result, revenue was ¥4,314 thousand and the segment loss was ¥160,824 thousand.」
Although the biomarker business continued to record a loss, the loss narrowed from ¥204,294 thousand in the previous fiscal year to ¥160,824 thousand. The previous fiscal year covered a 15-month accounting period. - FY2020-Q3MitigatedAnnual report
「As a result, revenue was ¥2,923 thousand and the segment loss was ¥122,412 thousand.」
The biomarker business recorded revenue of ¥2,923 thousand and a segment loss of ¥122,412 thousand. The loss narrowed from the segment loss of ¥135,985 thousand in the same period of the previous year shown for comparison. - FY2020-Q2RestatedAnnual report
「As a result, revenue was ¥1,431 thousand and the segment loss was ¥79,847 thousand.」
The biomarker business recorded revenue of ¥1,431 thousand and a segment loss of ¥79,847 thousand. No year-on-year profit or loss comparison was made because the periods covered were different. - FY2020-Q1RestatedAnnual report
「As a result, revenue was ¥513 thousand and the segment loss was ¥32,967 thousand.」
The biomarker business recorded revenue of ¥513 thousand and a segment loss of ¥32,967 thousand. No comparison with the previous quarter was made because of the change in the fiscal year-end. - FY2019WorsenedAnnual report
「Revenue was ¥405 thousand and the segment loss was ¥204,294 thousand.」
The biomarker business's segment loss widened from ¥185,305 thousand in the previous consolidated fiscal year to ¥204,294 thousand. - FY2019-Q3RestatedAnnual report
「As a result, revenue was ¥30 thousand and the segment loss was ¥172,360 thousand.」
The biomarker business recorded revenue of ¥30 thousand and a segment loss of ¥172,360 thousand. No comparison with the same quarter of the previous year was made because this was an irregular fiscal period. - FY2019-Q2MitigatedAnnual report
「As a result, revenue was ¥20 thousand, down 96.6% year on year, and the segment loss was ¥135,985 thousand, compared with a segment loss of ¥145,993 thousand in the same period of the previous year.」
Revenue from the biomarker business declined, while the segment loss narrowed from ¥145,993 thousand in the same period of the previous year to ¥135,985 thousand. - FY2019-Q1MitigatedAnnual report
「As a result, revenue was ¥20 thousand, up 85.2% year on year, and the segment loss was ¥84,841 thousand, compared with a segment loss of ¥106,445 thousand in the same period of the previous year.」
Revenue from the biomarker business rose 85.2% year on year, while the segment loss narrowed from ¥106,445 thousand in the same period of the previous year to ¥84,841 thousand. - FY2018-Q4WorsenedAnnual report
「As a result, revenue was ¥10 thousand, down 7.4% year on year, and the segment loss was ¥49,142 thousand, compared with a segment loss of ¥44,112 thousand in the same period of the previous year.」
The biomarker business recorded lower revenue, while the segment loss widened from ¥44,112 thousand in the same period of the previous year to ¥49,142 thousand. - FY2018-Q2WorsenedAnnual report
「As a result, revenue was ¥590 thousand, down 15.6% year on year, and the segment loss was ¥145,993 thousand, compared with a segment loss of ¥135,347 thousand in the same period of the previous year.」
The biomarker business recorded lower revenue, while the segment loss widened from ¥135,347 thousand in the same period of the previous year to ¥145,993 thousand. - FY2018-Q1WorsenedAnnual report
「As a result, revenue was ¥10 thousand, down 97.8% year on year, and the segment loss was ¥106,445 thousand, compared with a segment loss of ¥72,610 thousand in the same period of the previous year.」
Revenue from the biomarker business fell 97.8% year on year, while the segment loss widened from ¥72,610 thousand in the same period of the previous year to ¥106,445 thousand. - FY2017-Q4WorsenedAnnual report
「As a result, revenue was ¥10 thousand, down 88.0% year on year, and the segment loss was ¥44,112 thousand, compared with a segment loss of ¥37,564 thousand in the same period of the previous year.」
Revenue from the biomarker business fell 88.0% year on year, while the segment loss widened from ¥37,564 thousand in the same period of the previous year to ¥44,112 thousand. - FY2017WorsenedAnnual report
「As a result, revenue was ¥722 thousand, down 97.7% year on year, and the segment loss was ¥198,005 thousand, compared with a segment loss of ¥60,452 thousand in the same period of the previous year.」
Revenue from the biomarker business fell sharply, while the segment loss widened. The start of full-scale investment in product development and clinical development, among other areas, was also cited as a factor. - FY2017-Q2WorsenedAnnual report
「As a result, revenue was ¥700 thousand, down 97.7% year on year, and the segment loss was ¥135,347 thousand, compared with a segment loss of ¥35,731 thousand in the same period of the previous year.」
Revenue from the biomarker business fell 97.7% year on year, while the segment loss widened from ¥35,731 thousand in the same period of the previous year to ¥135,347 thousand. - FY2017-Q1WorsenedAnnual report
「As a result, revenue was ¥480 thousand, down 98.4% year on year, and the segment loss was ¥72,610 thousand, compared with a segment loss of ¥14,002 thousand in the same period of the previous year.」
Revenue from the biomarker business fell 98.4% year on year, while the segment loss widened from ¥14,002 thousand in the same period of the previous year to ¥72,610 thousand. - FY2016-Q4First statedAnnual report
「As a result, revenue was ¥90 thousand, down 69.0% year on year, and the segment loss was ¥37,564 thousand, compared with a segment loss of ¥18,530 thousand in the same period of the previous year.」
The biomarker business recorded revenue of ¥90 thousand and a segment loss of ¥37,564 thousand.